Lucinactant
Also known as: KL4 peptide surfactant, KL4 surfactant, lucinactant intratracheal suspension, Sinapultide, Surfaxin
Source Lucinactant at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Lucinactant is a synthetic pulmonary surfactant that contains the peptide sinapultide, a designed mimic of human surfactant protein B. It is administered directly into the airways of newborns and infants to prevent or treat respiratory distress syndrome (RDS) and has been explored for acute hypoxemic respiratory failure, meconium aspiration syndrome, and aerosol delivery.
Mechanism of Action
Sinapultide reproduces the activity of surfactant protein B by inserting into the phospholipid monolayer that lines alveoli, rapidly reducing surface tension during breathing cycles. This lowers the work of ventilation, improves lung compliance, and helps keep alveoli open. The synthetic peptide is engineered to resist oxidative and protein‑induced inactivation, preserving surfactant function in the inflamed neonatal lung.
What the Research Shows
Randomised, double‑blind prophylaxis trials in premature infants showed that lucinactant lowered the incidence of RDS at 24 hours and reduced RDS‑related mortality at 14 days compared with colfosceril palmitate and beractant, and was non‑inferior to poractant alfa for survival without bronchopulmonary dysplasia. A meta‑analysis reported efficacy comparable to animal‑derived surfactants and suggested greater resistance to oxidative inactivation. Pilot studies of aerosolised lucinactant demonstrated feasibility and safety, while a phase II trial in infants with acute hypoxemic respiratory failure found it generally safe, improved oxygenation and reduced need for retreatment, with a ventilation‑time benefit in a small severe‑injury subgroup. A small bronchoalveolar‑lavage trial in meconium aspiration syndrome showed safety and trends toward earlier ventilator weaning.
Reported Benefits
Clinical data indicate that lucinactant effectively prevents RDS in preterm infants, achieving mortality and bronchopulmonary dysplasia outcomes similar to animal‑derived surfactants. Its synthetic nature eliminates the risk of pathogen transmission and may reduce immunogenicity. In vitro studies suggest greater stability against oxidative damage, and early‑phase trials hint at improved oxygenation and reduced retreatment in acute hypoxemic respiratory failure, as well as potential utility in meconium aspiration syndrome lavage.
Limitations of the Evidence
Evidence is strongest for prophylaxis of neonatal RDS; comparative trials have reported higher rates of pneumothorax and bronchopulmonary dysplasia with synthetic surfactants versus natural preparations. Data on aerosol delivery, acute respiratory failure, and meconium aspiration are limited to small pilot studies, and larger phase III trials are pending. Long‑term safety and efficacy beyond the neonatal period remain insufficiently characterized.
Safety Considerations
Lucinactant is generally well tolerated. Reported adverse events are transient and linked to the intubation and dosing procedure, including brief bradycardia and desaturation during administration. No increase in mortality or major complications was observed in neonatal trials. Reviews note that synthetic surfactants as a class may carry a higher risk of pneumothorax compared with natural surfactants, although lucinactant‑specific data did not demonstrate a clear excess. Monitoring during and after dosing is advised.
How It Is Administered
Lucinactant is supplied as an intratracheal suspension and is instilled directly into the airway, typically soon after birth for prophylaxis or during mechanical ventilation for rescue therapy. Doses used in trials have been around 175 mg/kg for acute hypoxemic failure. Aerosolised formulations have been investigated experimentally but are not yet approved for clinical use.
Routes of Administration
Goals & Uses
- Treat neonatal respiratory distress syndromeTherapeuticHigh
- Prevention of Respiratory Distress Syndrome (RDS)Neonatal PulmonologyHigh
- Reduce need for mechanical ventilationClinical OutcomeModerate
- Improvement of lung compliance in premature infantsRespiratory SupportHigh
- Treatment of established RDSNeonatal PulmonologyModerate
- Aerosolized surfactant delivery (investigational)Drug Delivery InnovationLow
Contraindications
- Use in non-premature or term infants without surfactant deficiencyIndication MismatchModerate
- Known hypersensitivity to lucinactant or any componentAllergyHigh
- Pulmonary hemorrhageRespiratoryHigh
- Congenital airway malformationsStructuralModerate
Adverse Effects
- Endotracheal tube blockage or refluxProceduralUncommon
- Pulmonary edemaRespiratoryUncommon
- Oxygen desaturationPulmonaryCommon
- Pallor or cyanosisCardiovascular/RespiratoryCommon
- Pulmonary hemorrhagePulmonaryUncommon
- BradycardiaCardiovascularCommon
Drug Interactions
- Inhaled nitric oxideLow
Population Constraints
- Infants with active infection or sepsisConcurrent IllnessRelative
- Premature neonates (primary population)Age/developmentalAbsolute
- Preterm infants < 37 weeks gestational ageAge/gestationalAbsolute
- Infants with congenital anomalies affecting lung developmentStructural AnomalyRelative
Regulatory Status
- European UnionUnapprovedNo marketing authorization.
- United StatesWithdrawnApproved: Neonatal respiratory distress syndromeApproved 2012, marketing discontinued 2017.
- United KingdomUnapprovedNo marketing authorization.
FDA approved in 2012 for neonatal RDS; marketing discontinued in 2017; not approved in the EU or UK.
Evidence & Sources
- Journal ArticleModerateMoen MD, Perry CM, Wellington K2005-01-01T00:00:00.000000Z
- Journal ArticleModerateJordan BK, Donn SM2013-01-01T00:00:00.000000Z
- Journal ArticleModerateGhodrat M2006-01-01T00:00:00.000000Z
- Journal ArticleModerateDonn SM, Sinha SK2008-01-01T00:00:00.000000Z
- Journal ArticleModerateThomas NJ, et al.2012-01-01T00:00:00.000000Z
- Journal ArticleModerateWiswell TE, et al.2002-01-01T00:00:00.000000Z
Frequently Asked Questions
What condition is lucinactant primarily used to treat?
Lucinactant is approved for the prophylaxis and treatment of respiratory distress syndrome in premature infants, a condition caused by surfactant deficiency that impairs lung function at birth.
How does lucinactant differ from animal‑derived surfactants?
It is a fully synthetic preparation containing a peptide that mimics surfactant protein B, eliminating the risk of infectious disease transmission and offering consistent manufacturing, while showing comparable efficacy in clinical trials.
Can lucinactant be given without intubation?
Current approved use requires intratracheal delivery via an endotracheal tube. Aerosolised delivery has been explored in early studies but is not yet an approved or routine method.
What safety concerns should clinicians watch for?
Transient bradycardia and desaturation during dosing are the most common procedural adverse events. Clinicians should monitor heart rate and oxygenation closely during and after administration.
Is there evidence for lucinactant in conditions other than RDS?
Small pilot trials suggest possible benefit in acute hypoxemic respiratory failure and meconium aspiration syndrome, but data are limited and larger studies are needed before routine use in these settings.
What is Lucinactant?
Lucinactant is a synthetic pulmonary surfactant that contains the peptide sinapultide, a designed mimic of human surfactant protein B. It is administered directly into the airways of newborns and infants to prevent or treat respiratory distress syndrome (RDS) and has been explored for acute hypoxemic respiratory failure, meconium aspiration syndrome, and aerosol delivery.
What is Lucinactant used for?
Lucinactant is educationally associated with: Treat neonatal respiratory distress syndrome, Prevention of Respiratory Distress Syndrome (RDS), Reduce need for mechanical ventilation, Improvement of lung compliance in premature infants, Treatment of established RDS, Aerosolized surfactant delivery (investigational). Educational only — not medical advice.
How is Lucinactant administered?
Recorded routes of administration: Endotracheal, Intratracheal.
What are the potential side effects of Lucinactant?
Reported adverse effects include: Endotracheal tube blockage or reflux, Pulmonary edema, Oxygen desaturation, Pallor or cyanosis, Pulmonary hemorrhage, Bradycardia. This list is not exhaustive — consult a qualified clinician.
Who should avoid Lucinactant?
Recorded contraindications: Use in non-premature or term infants without surfactant deficiency, Known hypersensitivity to lucinactant or any component, Pulmonary hemorrhage, Congenital airway malformations. Consult a qualified clinician before use.